Stock Analiz

Compugen Ltd. CGEN

Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2000 · data as of November 13, 2026

$2.10Market cap $199M
Open the interactive analysis →

Compugen Ltd. (CGEN) is a healthcare company listed in the US with a market value of about $199M. In fiscal year 2025 it had revenue of $73M and net income of $35M, a net margin of 48.6%.

Its overall Stock Analiz score is 3.2 out of 5 (average). The strongest part is financial health (5/5); the weakest is shareholder returns (1/5).

Key numbers: a P/E of 5.6, a price to free cash flow of 6.3, 5-year revenue growth of 105% a year, a 5-year average ROIC of -15%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 32% above the current price.

About Compugen

Compugen is listed in the US and classified in biotechnology: biological products (no diagnostic substances), IPO year 2000. Revenue went from $12M in 2014 to $73M in 2025, growth of about 17.5% a year. It was profitable in 1 of the last 10 years in our data. It spends 31% of revenue on research and development.

Score: 3.2 / 5

Value4/5
Future growth4/5
Track record2/5
Financial health5/5
Shareholder returns1/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • Strong R&D investment or growth above 20%

Checks not passed

  • PEG below 1.5
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year average ROIC above 12%
  • Profitable 5 years in a row
  • Pays a dividend
  • Share count down over 3 years (buybacks)
  • 20% to 100% of free cash flow returned to shareholders

Valuation

P/E (TTM)5.6
Forward P/E—
P/FCF6.3
P/S2.7
P/B1.9
EV/EBITDA3.2
PEG—
Dividend yield0.00%
FCF yield15.8%
Shareholder yield0.0%
Intrinsic value vs. price+32%

Growth and quality

Revenue growth (1 yr)161.1%
Revenue growth (5 yrs, per year)105.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-215.6%
ROIC (5-yr avg.)-14.6%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 10 years

Fiscal year2025202420232022202120202019201820172016
Revenue$73M$28M$33M$8M$6M$2M—$18M—$712000
Net income$35M-$14M-$19M-$34M-$34M-$30M-$27M-$23M-$37M-$32M
Free cash flow$31M$49M-$36M-$35M-$23M-$28M-$28M-$13M-$31M-$22M
EPS (diluted)$0.37$-0.15$-0.20$-0.36$-0.36$-0.31$-0.29$-0.24$-0.39$-0.33
Net margin48.6%-51.1%-56.0%-449.2%-570.0%-1484.9%—-127.0%—-4425.0%
ROIC29.6%-20.3%-15.3%-35.1%-32.0%-25.6%-67.2%-49.3%-100.9%-40.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is Compugen’s P/E ratio?

About 5.6, based on the last twelve months of diluted earnings per share.

Is Compugen stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 32% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Compugen pay a dividend?

Not currently.

Is Compugen a good stock to buy?

We do not give buy or sell advice. Compugen scores 3.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.